These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34375617)

  • 41. Autoinflammatory conditions: when to suspect? How to treat?
    Grateau G; Duruöz MT
    Best Pract Res Clin Rheumatol; 2010 Jun; 24(3):401-11. PubMed ID: 20534373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introduction to autoinflammatory syndromes and diseases.
    Abramovits W; Oquendo M
    Dermatol Clin; 2013 Jul; 31(3):363-85. PubMed ID: 23827242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autoinflammatory disease reloaded: a clinical perspective.
    Kastner DL; Aksentijevich I; Goldbach-Mansky R
    Cell; 2010 Mar; 140(6):784-90. PubMed ID: 20303869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs.
    Piscianz E; Cuzzoni E; Sharma R; Tesser A; Sapra P; Tommasini A
    Curr Med Chem; 2018; 25(24):2797-2810. PubMed ID: 28901270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary.
    Butler D; Shinkai K
    Dermatol Clin; 2013 Jul; 31(3):427-35. PubMed ID: 23827245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.
    Schett G; McInnes IB; Neurath MF
    N Engl J Med; 2021 Aug; 385(7):628-639. PubMed ID: 34379924
    [No Abstract]   [Full Text] [Related]  

  • 48. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What's New in Genetic Skin Diseases.
    Hill CR; Theos A
    Dermatol Clin; 2019 Apr; 37(2):229-239. PubMed ID: 30850045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates.
    Coricello A; Mesiti F; Lupia A; Maruca A; Alcaro S
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32707925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor.
    Kataoka S; Kawashima N; Okuno Y; Muramatsu H; Miwata S; Narita K; Hamada M; Murakami N; Taniguchi R; Ichikawa D; Kitazawa H; Suzuki K; Nishikawa E; Narita A; Nishio N; Yamamoto H; Fukasawa Y; Kato T; Yamamoto H; Natsume J; Kojima S; Nishino I; Taketani T; Ohnishi H; Takahashi Y
    J Allergy Clin Immunol; 2021 Aug; 148(2):639-644. PubMed ID: 33727065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
    Chen M; Dai SM
    Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
    Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
    J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The body against self: autoinflammation and autoimmunity.
    Borella E; Palma L; Zen M; Bettio S; Nalotto L; Gatto M; Domeneghetti M; Laccarino L; Punzi L; Doria A
    Isr Med Assoc J; 2014 Oct; 16(10):608-10. PubMed ID: 25438443
    [No Abstract]   [Full Text] [Related]  

  • 57. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
    Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
    Svoboda SA; Johnson N; Phillips M
    Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of JAK inhibitors in Ulcerative Colitis.
    Ferrante M; Sabino J
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.